If we assume that JNK is a general MMP2 inhibitor in gliomas, even patients with normal WNK2 expression treated with a JNK inhibitor would better benefit from the treatment, both because of the invasion inhibition, and by the enhancement of temozolomide cytotoxicity. The gene discussed is MAPK8; the disease is glioma.